Hormone health
By Dr. K.D. LanierFebruary 23, 2026 · Clinical review required before public release · IDR-HOR-001
1. Which symptoms are we treating?
Name the problem clearly. Treatment is easier to evaluate when you know what improvement should look like.
2. Could something else be contributing?
Fatigue, mood changes, poor sleep, and weight changes can have several causes. A clinician may need to review medications, sleep, thyroid concerns, anemia, mental health, or other conditions.
3. Which hormone and route are you recommending?
Estrogen, progesterone, and related therapies come in different formulations and routes. The choice depends on symptoms, whether you have a uterus, medical history, preferences, and risk factors.
4. Is the product FDA-approved or compounded?
Some FDA-approved hormones are chemically identical to hormones produced by the body. The word bioidentical does not automatically mean compounded or safer. ACOG recommends FDA-approved formulations when they can meet the clinical need because evidence and quality controls are stronger.
5. What are my personal risks?
Risk depends on factors such as age, timing, dose, route, and history of blood clots, stroke, heart disease, liver disease, or certain cancers. Your clinician should explain how those factors apply to you.
6. How will we monitor the plan?
Ask when symptoms and side effects will be reviewed, what preventive care remains important, and what warning signs require prompt attention.
7. When will we reconsider?
Needs can change. Revisit the lowest effective dose, ongoing benefit, and personal preferences over time.
You deserve relief and a clear explanation. At IDARA Truforme, the conversation begins with your lived experience and proceeds with clinical judgment.
Educational content only. It does not replace personal medical care.
Evidence and review notes
These sources support the educational context. An IDARA clinician must confirm current evidence, service availability, and final claims before public release.


